Evaluation Of Anemia Management In Ckd Patients: Effectiveness Of Erythropoiesis-Stimulating Agents (Esas)

Abstract

Margarets NM jointly wrote this study with Panzer AD and Lai RC and Sanon M along with Michalopoulos E and Redmond AM and Moghadam R and Chambers JD. Variation in health plan coverage of ESAs for anaemia due to chronic kidney disease. Journal of Managed Care & Specialty Pharmacy. 2021 Sep;27(9):1221-9.

Objectives:

One goal of this study is to assess both the haemoglobin-level improvement and transfusion need reduction through the use of ESAs among CKD patients with anaemia.

Study design:  A prospective study.

Place and duration of study: Jan 2021 to Jan 2023

Methods:

The Department Of Nephrology  Mercy Teaching Hospital – Peshawar  served as the study site to observe 120 CKD stage 3–5 patients with anaemia in this prospective observational study. The patients received standard ESA therapy as part of the study which extended over six months. Patient Hb levels and transfusion frequency as well as adverse events received recorded documentation during the study. The study utilized SPSS 24.0 for statistical analysis while treating p<0.05 as the threshold for significance.

Results: 100 patients participated in the study whereas males made up 58 percent of the group; the participants had an average age of 56.4 ± 11.3 years. Study participants began the study with an average Hb level at 8.9 ± 0.7 g/dL and achieved 11.1 ± 1.1 g/dL six months later (p < 0.001). Patient transfusion need reduced drastically from 32.5% to 6.7% according to statistical analysis (p = 0.002). Out of the 100 patients, hypertension affected 15.8% while headache occurred in 6.7%.

Conclusion:

ESAs properly manage CKD patient anaemia by boosting their haemoglobin levels and helping them move away from blood transfusions. Treatment results for patients develop best when healthcare providers monitor regularly and tailor the medication dose according to individual needs and resolve any iron deficiencies